198 related articles for article (PubMed ID: 33280926)
21. A novel SETD3-ALK fusion in lung adenocarcinoma and sustained clinical response to crizotinib.
Dai S; Liu XQ; Wu Q; Du CM; Liu Q; Xue YY; Luo F; Li Y
Lung Cancer; 2023 Jan; 175():121-124. PubMed ID: 36495785
[TBL] [Abstract][Full Text] [Related]
22. Identification of triple gene fusion ALK-LRRN2, LTBP1-ALK, and HIP1-ALK in advanced lung adenocarcinoma and response to alectinib: A case report.
Ning S; Shi C; Zhang H; Li J
Medicine (Baltimore); 2021 Dec; 100(51):e27999. PubMed ID: 34941039
[TBL] [Abstract][Full Text] [Related]
23. Lysocardiolipin Acyltransferase 1-Anaplastic Lymphoma Receptor Tyrosine Kinase: A Novel Crizotinib-Sensitive Fusion Gene in Lung Adenocarcinoma.
Bu K; Lu Y; Liu X; Cheng C; Li B
J Thorac Oncol; 2020 Apr; 15(4):e55-e57. PubMed ID: 32216948
[No Abstract] [Full Text] [Related]
24. Molecular Modeling of ALK L1198F and/or G1202R Mutations to Determine Differential Crizotinib Sensitivity.
Chuang YC; Huang BY; Chang HW; Yang CN
Sci Rep; 2019 Aug; 9(1):11390. PubMed ID: 31388026
[TBL] [Abstract][Full Text] [Related]
25. Novel PNPT1-ALK fusion variant exerted significant benefit to crizotinib in NSCLC.
Jin L; Wang Y; Li S; Chen D; Zhao X
Lung Cancer; 2020 Aug; 146():382-384. PubMed ID: 32540202
[No Abstract] [Full Text] [Related]
26. Targeting SLMAP-ALK-a novel gene fusion in lung adenocarcinoma.
Pagan C; Barua S; Hsiao SJ; Mansukhani M; Saqi A; Murty V; Fernandes H
Cold Spring Harb Mol Case Stud; 2019 Jun; 5(3):. PubMed ID: 31160357
[TBL] [Abstract][Full Text] [Related]
27. HIP1-ALK, a novel ALK fusion variant that responds to crizotinib.
Fang DD; Zhang B; Gu Q; Lira M; Xu Q; Sun H; Qian M; Sheng W; Ozeck M; Wang Z; Zhang C; Chen X; Chen KX; Li J; Chen SH; Christensen J; Mao M; Chan CC
J Thorac Oncol; 2014 Mar; 9(3):285-94. PubMed ID: 24496003
[TBL] [Abstract][Full Text] [Related]
28. ALK inhibitors in the treatment of advanced NSCLC.
Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
[TBL] [Abstract][Full Text] [Related]
29. Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively.
Tao H; Liu Z; Mu J; Gai F; Huang Z; Shi L
Diagn Pathol; 2022 Feb; 17(1):27. PubMed ID: 35144623
[TBL] [Abstract][Full Text] [Related]
30. BRAF V600E mutation as a novel mechanism of acquired resistance to ALK inhibition in ALK-rearranged lung adenocarcinoma: A case report.
Sui A; Song H; Li Y; Guo L; Wang K; Yuan M; Chen R
Medicine (Baltimore); 2021 Feb; 100(8):e24917. PubMed ID: 33663128
[TBL] [Abstract][Full Text] [Related]
31. [Ceritinib as First-line Treatment for Advanced Lung Adenocarcinoma
with COX7A2L-ALK Fusion: A Case Report and Literature Review].
Yuan J; Pan R; Zhong W; Wang M
Zhongguo Fei Ai Za Zhi; 2023 Apr; 26(4):319-324. PubMed ID: 37183647
[TBL] [Abstract][Full Text] [Related]
32. DNA and RNA sequencing revealed a complex intergenic-ALK fusion in a lung adenocarcinoma patient who responded to TKI therapy.
Zhang J; Huang J; Li Q; Lin H; Luo Z; Chen R
Lung Cancer; 2021 Sep; 159():171-174. PubMed ID: 34266695
[No Abstract] [Full Text] [Related]
33. miR-100-5p confers resistance to ALK tyrosine kinase inhibitors Crizotinib and Lorlatinib in EML4-ALK positive NSCLC.
Lai Y; Kacal M; Kanony M; Stukan I; Jatta K; Kis L; Norberg E; Vakifahmetoglu-Norberg H; Lewensohn R; Hydbring P; Ekman S
Biochem Biophys Res Commun; 2019 Apr; 511(2):260-265. PubMed ID: 30791979
[TBL] [Abstract][Full Text] [Related]
34. A Novel Linc00308/D21S2088E Intergenic Region ALK Fusion and Its Enduring Clinical Responses to Crizotinib.
Zhang J; Zou C; Zhou C; Luo Y; He Q; Sun Y; Zhou J; Ke Z
J Thorac Oncol; 2020 Jun; 15(6):1073-1077. PubMed ID: 32217130
[No Abstract] [Full Text] [Related]
35. Response to ALK-TKIs in a lung adenocarcinoma patient harboring dual DCTN1-ALK and ALK-CLIP4 rearrangements.
Gao F; Gao F; Wu H; Lu J; Xu Y; Zhao Y
Thorac Cancer; 2022 Apr; 13(7):1088-1090. PubMed ID: 35212154
[TBL] [Abstract][Full Text] [Related]
36. GCC2-ALK as a targetable fusion in lung adenocarcinoma and its enduring clinical responses to ALK inhibitors.
Jiang J; Wu X; Tong X; Wei W; Chen A; Wang X; Shao YW; Huang J
Lung Cancer; 2018 Jan; 115():5-11. PubMed ID: 29290262
[TBL] [Abstract][Full Text] [Related]
37. Background and rationale of the eXalt3 trial investigating X-396 in the treatment of ALK+ non-small-cell lung cancer.
Singhi EK; Horn L
Future Oncol; 2018 Aug; 14(18):1781-1787. PubMed ID: 29506392
[TBL] [Abstract][Full Text] [Related]
38. Favorable predictors for survival in advanced ALK-positive non-small cell lung cancer patients beyond crizotinib resistance.
Xu H; Yang G; Yang L; Yang Y; Ma D; Li J; Hao X; Xing P; Wang Y
Thorac Cancer; 2019 May; 10(5):1096-1102. PubMed ID: 30920172
[TBL] [Abstract][Full Text] [Related]
39. A rare double ALK fusion variant EML4-ALK and CDK15-ALK in lung adenocarcinoma and response to crizotinib: A case report.
Guo J; Shi J; Yao M; Jin Y; Liu D; Liu W; Wang K; Jiang D
Medicine (Baltimore); 2020 Nov; 99(45):e22631. PubMed ID: 33157918
[TBL] [Abstract][Full Text] [Related]
40. Identification of a Novel RBPMS-ROS1 Fusion in an Adolescent Patient With Microsatellite-instable Advanced Lung Adenocarcinoma Sensitive to Crizotinib: A Case Report.
Zhang Y; Yu M; Yuan M; Chen R; Huang MJ
Clin Lung Cancer; 2020 Mar; 21(2):e78-e83. PubMed ID: 31722815
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
